Abstract
Objective
To investigate the efficacy of gonadotropin releasing hormone antagonist (GnRH) in poor responders undergoing in vitro fertilization.
Study design
Ninety-six patients with poor ovarian response in previous treatment cycles were prospectively randomized into two groups. Forty-four patients were stimulated with GnRH antagonist multidose protocol and 45 patients received a standard long agonist protocol. Ovarian response was evaluated by transvaginal ultrasound and hormonal parameters. Cycle characteristics and treatment outcomes were statistically compared between groups.
Results
There was significantly reduced duration of stimulation and consumption of gonadotrophins in the antagonist group when compared to the agonist group. The estradiol concentrations on the day of human chorionic gonadotropin (hCG) injection, the number of oocytes retrieved, and the number of embryos transferred were similar for both groups. In the antagonist group, eight (18.1%) ongoing pregnancies were achieved and in the agonist group, ten (22.2%) clinical pregnancies were achieved but the difference was not statistically significant.
Conclusion
The present study was not powered to detect clinically relevant differences between two protocols in outcomes such as pregnancy rate, with confidence.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Tarlatzis BC, Zepiridis L, Grimbizis G, Bontis J (2003) Clinical management of low ovarian response to stimulation for IVF: a systematic review. Hum Reprod Update 9:61–76
Hofmann GE, Toner JP Muasher SJ, Jones GS (1989) High-dose follicle-stimulating hormone (FSH) ovarian stimulation in low-responder patients for in vitro fertilization. J In Vitro Fert Embryo Transf 6:285–289
De Placido G, Alviggi C, Mollo A, Strina I, Varricchio MT, Molis M (2000) Recombinant follicle stimulating hormone is effective in poor responders to highly purified follicle stimulating hormone. Hum Reprod 15:17–20
Karacan M, Erkan H, Karabulut O, Sarıkamış B, Çamlıbel T, Benhabib M (2001) Clinical pregnancy rates in an IVF program. Use of the flare-up protocol after failure with long regimens of GnRH-a. J Reprod Med 46:485–489
Muasher SJ (1993) Treatment of low responders. J Assist Reprod Genet 10:112–114
Olivennes F, Alvarez S, Bouchard P, Franchin R, Salat-Baroux J, Frydman R (1998) The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg. Hum Reprod 13:2411–2414
Fasouliotis SJ, Simon A, Laufer N (2000) Evaluation and treatment of low responders in assisted reproductive technology: a challenge to meet. J Assist Reprod Genet 17:357–373
Griesinger G, Diedrich K, Tarlatzis BC, Kolibianakis EM (2006) GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. Reprod Biomed Online 13:628–638
Marci R, Caserta D, Dolo V, Tatone C, Pavan A, Moscarini M (2005) GnRH antagonist in IVF poor-responder patients: results of a randomized trial. Reprod Biomed Online 11:189–193
Germond M, Senn A, Reymond O et al (1990) Why lose an in vitro fertilization cycle when stimulation fails? Fertil Steril 53:936–938
Cheung LP et al (2005) GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial. Hum Reprod 20:616–621
Fasouliotis SJ, Laufer N, Sabbagh-Ehrlich S, Lewin A, Hurwitz A, Simon A (2003) Gonadotropin-releasing hormone (GnRH)-antagonist versus GnRH-agonist in ovarian stimulation of poor responders undergoing IVF. J Assist Reprod Genet 20:455–460
Nikolettos N, Al-Hasani S, Felberbaum R et al (2001) Gonadotropin-releasing hormone antagonist protocol: a novel method of ovarian stimulation in poor responders. Eur J Obstet Gynecol Reprod Biol 97:202–207
Copperman AB (2003) Antagonists in poor-responder patients. Fertil Steril 80:16–24
Cedrin-Durnerin I, Grange-Dujardin D, Laffy A et al (2004) Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study. Hum Reprod 19:1979–1984
Kolibianakis EM, Zikopoulos K, Schiettecatte J et al (2004) Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF. Hum Reprod 19:2490–2496
Ragni G, Vegetti W, Riccaboni A, Engl B, Brigante C, Crosignani PG (2005) Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome. Hum Reprod 20:2421–2425
Ben-Rafael Z, Lipitz S, Bider D, Mashiach S (1991) Ovarian hyporesponsiveness in combined gonadotropin-releasing hormone agonist and menotropin therapy is associated with low serum follicle-stimulating hormone levels. Fertil Steril 55:272–275
Sheehan KL, Casper RF, Yen SS (1982) Luteal phase defects induced by an agonist of luteinizing hormone-releasing factor: a model for fertility control. Science 215:170–172
Diedrich K, Diedrich C, Santos E et al (1994) Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod 9:788–791
Xavier P, Gamboa C, Calejo L et al (2005) A randomised study of GnRH antagonist (cetrorelix) versus agonist (busereline) for controlled ovarian stimulation: effect on safety and efficacy. Eur J Obstet Gynecol Reprod Biol 120:185–189
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tazegül, A., Görkemli, H., Özdemir, S. et al. Comparison of multiple dose GnRH antagonist and minidose long agonist protocols in poor responders undergoing in vitro fertilization: a randomized controlled trial. Arch Gynecol Obstet 278, 467–472 (2008). https://doi.org/10.1007/s00404-008-0620-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-008-0620-9